|Application ||WB, IHC-P, E|
|Calculated MW||42508 Da|
|Antigen Region||21-50 aa|
|Other Names||Proteinase-activated receptor 3, PAR-3, Coagulation factor II receptor-like 2, Thrombin receptor-like 2, F2RL2, PAR3|
|Target/Specificity||This F2RL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 21-50 amino acids from the N-terminal region of human F2RL2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||F2RL2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis.|
|Cellular Location||Cell membrane; Multi-pass membrane protein.|
|Tissue Location||Highest expression in the megakaryocytes of the bone marrow, lower in mature megakaryocytes, in platelets and in a variety of other tissues such as heart and gut|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Coagulation factor II (thrombin) receptor-like 2 (F2RL2) is a member of the large family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins. F2RL2 is also a member of the protease-activated receptor family and activated by thrombin. F2RL2 is activated by proteolytic cleavage of its extracellular amino terminus. The new amino terminus functions as a tethered ligand and activates the receptor. F2RL2 is a cofactor for F2RL3 activation by thrombin. It mediates thrombin-triggered phosphoinositide hydrolysis and is expressed in a variety of tissues.
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Popovic, M., et al. J. Thromb. Thrombolysis 30(2):164-171(2010)
Van Laer, L., et al. Eur. J. Hum. Genet. 18(6):685-693(2010)
Wysoczynski, M., et al. Mol. Cancer Res. 8(5):677-690(2010)
Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.